State Street Corp Athersys, Inc Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.18 - $0.86 $549,177 - $2.62 Million	-3,050,986 Reduced 80.68%	730,398 $190,000
Q1 2022 May 16, 2022	BUY	$0.6 - $1.06 $120,642 - $213,134	201,070 Added 5.62%	3,781,384 $2.29 Million
Q4 2021 Feb 14, 2022	SELL	$0.85 - $1.4 $169,499 - $279,175	-199,411 Reduced 5.28%	3,580,314 $3.23 Million
Q3 2021 Nov 15, 2021	BUY	$1.33 - $1.77 $195,040 - $259,565	146,647 Added 4.04%	3,779,725 $5.03 Million
Q2 2021 Aug 16, 2021	SELL	$1.41 - $1.94 $12.3 Million - $17 Million	-8,753,432 Reduced 70.67%	3,633,078 $5.23 Million
Q1 2021 May 17, 2021	BUY	$1.61 - $2.77 $4.36 Million - $7.5 Million	2,707,859 Added 27.98%	12,386,510 $22.3 Million
Q4 2020 Feb 16, 2021	SELL	$1.55 - $2.24 $3.66 Million - $5.29 Million	-2,363,603 Reduced 19.63%	9,678,651 $16.9 Million
Q3 2020 Nov 10, 2020	BUY	$1.91 - $3.08 $198,307 - $319,784	103,826 Added 0.87%	12,042,254 $23.5 Million
Q2 2020 Aug 14, 2020	BUY	$1.97 - $3.98 $17.9 Million - $36.2 Million	9,104,237 Added 321.23%	11,938,428 $33 Million
Q1 2020 May 11, 2020	BUY	$1.17 - $3.0 $3.32 Million - $8.5 Million	2,834,191 New	2,834,191 $8.5 Million

Ticker ATHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 305,110,016
Market Cap $3.05M
Description
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product i...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.